EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Mirikizumab is Equally Effective in Ustekinumab-Exposed and Ustekinumab-Naïve Patients with UC: A Multicentre Real-World Cohort

Mohmmed Tauseef Sharip iD, Dharmaraj Durai, Eva Vayreda, Nurulamin M Noor, Anushka Herath, Achini Withanachchi, Robin Dart, Sreedhar Subramanian, Miles Parkes, Mark A Samaan, Tim Raine, Peter M Irving

Crohn's & Colitis 360 · 19.06.2026

DOI: 10.1093/crocol/otag065 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Crohn's & Colitis 360, online erschienen am 19.06.2026. Verfasst von Mohmmed Tauseef Sharip und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Cambridge University Hospital NHS Trust, Cambridge, United Kingdom. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Mirikizumab, a selective IL-23p19 monoclonal antibody, has demonstrated efficacy in moderate-to-severe ulcerative colitis (UC) although real-world data are limited. In addition, registrational trials excluded patients previously treated with ustekinumab, which targets the IL-12/23 p40 subunit. We aimed to evaluate the real-world effectiveness and safety of mirikizumab in a multicentre UK cohort of patients with UC, including those with prior ustekinumab exposure.

Methods

A retrospective observational study was conducted across three tertiary UK centres. Adults with confirmed UC who received mirikizumab and had ≥12 weeks of follow-up were included. Data on demographics, disease activity (SCCAI, UCEIS), biomarkers (CRP, faecal calprotectin), and treatment persistence were analysed at 3 and 6 months. Outcomes were compared between ustekinumab-exposed and -naïve patients.

Results

Among 100 patients (36 ustekinumab-exposed), treatment persistence at 3 months was 72% with no significant difference between groups. SCCAI scores decreased from 5.8 to 3.3 at 3 months (p < 0.00001), and faecal calprotectin decreased from 1094 µg/g to 586 µg/g (p = 0.006). UCEIS scores (n = 36) improved significantly post-induction (mean 4.4 to 2.7, p < 0.000001). Multivariable logistic regression did not reveal any factors associated with treatment persistence, including prior ustekinumab exposure. Adverse events were infrequent and mild.

Conclusion

Mirikizumab is effective and well tolerated in a real-world UC population, including patients with prior ustekinumab exposure. These findings support the use of IL-23p19 inhibition regardless of previous IL-12/23 blockade.

Schlagwörter

Stichwörter der Autor:innen

mirikizumabp19 inhibitorsulcerative colitisustekinumab

Autor:innen und Institutionen

  • Department of Gastroenterology, Cambridge University Hospital NHS Trust, Cambridge, United Kingdom.
  • Department of Medicine, University of Cambridge, Cambridge, United Kingdom.
  • Gastroenterology Department, Cardiff and Vale University Health Board, Cardiff, United Kingdom.
  • Department of Gastroenterology, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom.
  • Department of immunobiology, School of Immunology and Microbial Sciences, King's College London, United Kingdom.

ORCID-Profile: Mohmmed Tauseef Sharip

Zitieren

APA

Sharip, M. T., Durai, D., Vayreda, E., Noor, N. M., Herath, A., Withanachchi, A., Dart, R., Subramanian, S., Parkes, M., Samaan, M. A., Raine, T., & Irving, P. M. (2026). Mirikizumab is Equally Effective in Ustekinumab-Exposed and Ustekinumab-Naïve Patients with UC: A Multicentre Real-World Cohort. Crohn's & Colitis 360. https://doi.org/10.1093/crocol/otag065

Vancouver

Sharip MT, Durai D, Vayreda E, Noor NM, Herath A, Withanachchi A, et al. Mirikizumab is Equally Effective in Ustekinumab-Exposed and Ustekinumab-Naïve Patients with UC: A Multicentre Real-World Cohort. Crohn's & Colitis 360. 2026. doi:10.1093/crocol/otag065

BibTeX
@article{Sharip2026,
  author = {Sharip, Mohmmed Tauseef and Durai, Dharmaraj and Vayreda, Eva and Noor, Nurulamin M and Herath, Anushka and Withanachchi, Achini and Dart, Robin and Subramanian, Sreedhar and Parkes, Miles and Samaan, Mark A and Raine, Tim and Irving, Peter M},
  title = {Mirikizumab is Equally Effective in Ustekinumab-Exposed and Ustekinumab-Naïve Patients with UC: A Multicentre Real-World Cohort},
  journal = {Crohn's & Colitis 360},
  year = {2026},
  doi = {10.1093/crocol/otag065}
}
Kostenlos starten →